PIPs have also shown effectiveness in targeting genetic aberrations other than single-base mutations, such as the case with copy-amplified MYCN [27], an aberration in neuroblastoma, where appreciable DNA damage and induced apoptosis were observable in MYCN-amplified neuroblastoma mouse models. This evidence concerns the gene MYCN and neuroblastoma.